{
  "ticker": "PYC",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02962761",
  "id": "02962761",
  "pages": 22,
  "price_sensitive": true,
  "date": "20250627",
  "time": "0911",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250627/pdf/06l5cl75k7mfp9.pdf",
  "summary": "### **Material Information Summary**  \n\n#### **Announcement Type: Program Update (PMS Drug Candidate - PYC-002)**  \n- **Key Highlights:**  \n  - **PYC-002 Efficacy Data:** Restores SHANK3 gene expression to normal levels in PMS patient-derived neurons, improving synaptic connectivity and neuronal communication.  \n  - **In Vivo Confirmation:** Demonstrated target engagement in key brain regions (hippocampus, prefrontal cortex, striatum, cerebellum) at safe doses.  \n  - **Clinical Pathway:** Plans to advance to IND-enabling studies, with clinical trials expected in **~12 months (2026)**.  \n  - **Presentation:** Data to be presented at **PMS Global Congress (Barcelona, 26\u201329 June 2025)**.  \n\n**No capital raising, financials, or trading-sensitive details disclosed.**  \n\n---  \n**Note:** Focused on material catalysts (clinical progress, data validation) impacting valuation. Omitted non-essential operational/technical details.",
  "usage": {
    "prompt_tokens": 6353,
    "completion_tokens": 210,
    "total_tokens": 6563,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-26T23:16:04.884303"
}